Sunstone Life Science Ventures
Sten Verland, PhD MSc, has extensive experience in the life sciences and venture capital sectors, currently serving as a Venture Partner and General Partner at Sunstone Life Science Ventures since May 2007. Sten is also the Chairman of Neumirna Therapeutics and holds positions as Non-Executive Director and Chairman of the Audit Committee at Minervax ApS, as well as Non-Executive Director at Anergis SA and Skovlyst Production A/S. In addition, Sten contributes as a member of various selection committees for Innovation Fund Denmark and serves as a Panel Member for the Centre for Research-based Innovation program at The Research Council of Norway. A seasoned entrepreneur, Sten founded Verland - Invest & Consulting in 1994. Academic credentials include a PhD in Immunology and an MSc in Biology and Mathematics from the University of Copenhagen.
This person is not in any offices
Sunstone Life Science Ventures
3 followers
Sunstone Life Science Ventures’ is a European, early-stage investor based in Copenhagen. Sunstone Life Science Ventures invests in drug development opportunities across the European Life Science sector, and prefer to make initial investment in companies raising Series A/B rounds based on solid in-vivo preclinical data and a well understood mechanism of action that fits well into the pathology.